Notably, a synergistic effect that inhibits growth and induces apoptosis was observed when imatinib was combined with a GLUT-1 inhibitor (WZB117) in imatinib-resistant gastrointestinal stromal tumor (GIST) cells, indicating the potential of such combinations for anticancer therapies [26]. The gene discussed is SLC2A1; the disease is gastrointestinal stromal tumor.